Metex

Methotrexate, the active ingredient in Metex, is an antimetabolite presented as a subcutaneous formulation for injection use. It is employed in the management of rheumatoid arthritis, psoriasis, certain leukemias and gestational trophoblastic disease, targeting inflammatory and proliferative processes.

GNH USA supplies Metex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation for import and distribution across multiple regions. Our logistics network ensures timely delivery with temperature‑controlled packaging where required.

Methotrexate is used in several disease categories, primarily targeting immune‑mediated and proliferative disorders.

- Rheumatoid arthritis: reduces joint inflammation, pain, and stiffness while slowing structural damage and preserving function. - Psoriasis: decreases skin plaque formation and scaling by limiting keratinocyte proliferation and inflammatory signaling. - Acute lymphoblastic leukemia: interferes with malignant cell DNA synthesis, leading to reduced replication and remission induction. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue, decreasing hCG levels and preventing disease progression. - Juvenile idiopathic arthritis: alleviates joint swelling and improves mobility in pediatric patients.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset that may require anti‑emetic therapy and can affect oral intake. - Fatigue and mouth sores: persistent tiredness accompanied by stomatitis or ulceration, often limiting daily activities. - Low blood cell counts (leukopenia, anemia): reduced white cells and red cells leading to infection risk, fatigue, and possible need for transfusion.

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis: significant elevation of liver enzymes or progressive scarring that may require discontinuation and specialist monitoring. - Pulmonary fibrosis or interstitial pneumonitis: inflammation and scarring of lung tissue causing breathlessness, cough, and reduced oxygen exchange. - Life‑threatening infection or bone‑marrow suppression: profound immunosuppression that can result in sepsis, requiring immediate hospitalization and aggressive antimicrobial therapy.

Key safety considerations for methotrexate include patient monitoring and avoidance of contraindicated situations. - Pregnancy contraindication: drug is teratogenic (Category X) and must not be used during pregnancy. - Liver monitoring: regular liver function tests are required to detect hepatotoxicity. - Blood count surveillance: complete blood counts should be checked frequently to identify bone‑marrow suppression. - Renal function assessment: dose adjustment or avoidance is needed in patients with impaired kidney function. - Concomitant drug caution: avoid NSAIDs and live vaccines while on therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines, influencing its efficacy and toxicity.

Major Interactions (Avoid): - NSAIDs (e.g., ibuprofen, naproxen): increase methotrexate plasma levels and risk of toxicity. - Sulfonamide antibiotics (e.g., trimethoprim‑sulfamethoxazole): potentiate bone‑marrow suppression. - Penicillins (e.g., ampicillin): may reduce renal clearance, raising methotrexate concentrations.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors (e.g., omeprazole): can alter methotrexate elimination and modestly increase exposure. - Azathioprine or leflunomide: combined immunosuppression may heighten infection risk. - Oral contraceptives: may reduce methotrexate efficacy, requiring monitoring of disease activity.